Prytek appoints Noga Knaz as CEO of its Venture Capital arm, Prytek Ventures


Prytek, a multinational technology group with a focus on building and investing in technologies and delivering managed services, announces that it has appointed Noga Knaz as its CEO of Prytek Ventures to provide the Corporate Venture Capital (CVC) arm with more management attention and concentrating on early-stage fintech startups.

As part of her role, Noga will be responsible for Prytek’s investment activities in early-stage companies that work with or contribute to the technology and services sectors of mature companies in the Group. Prytek’s venture capital assets are currently worth over $100 million, which among other things, are developing technologies for the services divisions of the Group. Its CVC portfolio includes several technology companies that the Group has invested in, such as BlackSwan, Apester, CyberHat, FICX, Orchestra, and Ezbob.

In her new role, Noga brings with her over 20 years of Financial Services experience and a wide variety of positions, from trading in stock exchanges, analysis, marketing and investment management. She was previously a partner in Rosario Capital and also served as their CEO and Vice Chairman. She also currently holds director positions at BIG, Hilan, and Altshuler-Shacham.

Andrey Yashunsky, CEO of Prytek says: “We are very happy to see a professional such as Noga joining the Venture Capital arm of Prytek. In her role she will be looking to continue investing in technologies for our corporate and managed services. The Venture Capital arm has served to build dozens of great tech solutions in the last few years, which are our divisions use to provide solutions to our clients.”

Noga Knaz, CEO of Prytek Ventures, adds: “I am delighted to be joining the Prytek family and growing the portfolio of tech solution providers. I look forward to leading Prytek Ventures’ growth and enhancing its value chain proposition.”


Sidney Kimmel Cancer Center at Jefferson Health Joins Caris Life Sciences’ Precision Oncology Alliance


Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.

For nearly 25 years, SKCC, one of 71 National Cancer Institute (NCI)-designated cancer centers in the U.S., has provided oncology patients in the Greater Philadelphia region the latest developments in cancer research, technology and treatment. Using the most advanced treatment methods and technologies, their physicians and researchers help lead the world’s new cancer therapies.

“Our mission is to improve the lives of cancer patients and their families through compassion, innovation and breakthrough discoveries,” said Karen E. Knudsen, MBA, Ph.D., EVP of Oncology Services and Enterprise Director of SKCC. “We value the POA’s collaborative efforts in advancing precision medicine and look forward to contributing our team’s expertise in treatment methods and technologies that will further accelerate scientific breakthroughs to benefit patients worldwide.”

“Physicians and researchers at SKCC have helped transform scientific discoveries into improved cancer treatments for their patients,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “The POA welcomes their multidisciplinary experience in precision oncology to further our efforts in maximizing patient outcomes through advanced diagnostic testing and molecular insights. We look forward to collaborating with all of their investigators across all tumor types.”

The Caris Precision Oncology Alliance includes 50 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 244,000 patients covering over 1,000,000 data points per patient.

“The POA is excited to work with SKCC’s world-renowned research faculty to develop and test cancer treatments designed to transform care, by improving both survival and quality of life for patients with cancer around the world,” said Brian J. Brille, Vice Chairman of Caris Life Sciences.


Lightnet Group Forges Partnership with Siam Commercial Bank


Singapore-based fintech company, Lightnet Pte. Ltd. (Lightnet Group), has announced a partnership with Siam Commercial Bank (SCB). The partnership makes remittance services accessible to all Thai bank accounts and anyone who has signed up for PromptPay, a government-sponsored service that enables instant bank-to-bank fund transfers.

Suvicha Sudchai, Chief Product Officer of Lightnet Group, says “SCB will be Lightnet Group’s settlement partner responsible for disbursing and clearing payments, facilitating the electronic payment processing and enabling frictionless real-time remittances to Thailand from anywhere in the world with lower fees.”

This partnership offers SCB additional international money transfer options through Lightnet Group’s channels. “Siam Commercial Bank has been a longtime supporter of fintech startups in Thailand, and our fintech investment arm, Digital Ventures Co. Ltd., is the largest venture capital fund in Thailand, with a total capital base of USD100 million. Fintech plays an essential role in SCB’s digital transformation, and we look forward to working with the Lightnet Group to revolutionize the global remittances industry,” says EVP, Payment Strategy and Digital Disruptive Technology, Srihanath Lamsam.

On the new partnership, Lightnet Group’s CEO and Vice Chairman, Tridbodi Arunanondchai says, “We are very proud to be working with SCB to facilitate cross-border remittances together with another trusted global fintech solution provider, SENTBE. SCB is one of the most reputable banks in Thailand and the technology investment the bank employs allows us to optimize our platform and reach our goals.”

Lightnet Group’s partnership with SCB and Sentbe extends the Lightnet Group’s reach further in line with its mission to promote financial mobility and inclusivity.